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Abstract
Background A pilot study of stereotactic body radiation
therapy (SBRT) followed by high-dose interleukin-2 (IL2) showed a higher than anticipated objective response
rate (ORR) among patients with metastatic melanoma
(MM). We performed a prospective randomized study to
determine if the ORR of SBRT + IL-2 was greater than IL-2
monotherapy in patients with advanced melanoma.
Methods Patients with MM who had adequate
physiological reserve for IL-2 and at least one site suitable
for SBRT were eligible. There was a 1:1 randomization to
SBRT + IL-2 or IL-2 monotherapy. Patients received one or
two doses of SBRT (20 Gy per fraction) with the last dose
administered 3 days before starting the first cycle of IL-2.
IL-2 (600,000 IU per kg via intravenous bolus infusion)
was given every 8 hours for a maximum of 14 doses with
a second cycle after a 2-week rest. Responding patients
received up to six IL-2 cycles. Patients assigned to IL-2
monotherapy who exhibited progression of melanoma
after cycle 2 were allowed to crossover and receive SBRT
and additional IL-2. Response Evaluation Criteria in Solid
Tumors 1.1 criteria were applied to non-irradiated lesions
for response assessment.
Results 44 patients were included in the analysis. The
ORR in the SBRT + IL-2 group was 54%: 21% complete
response (CR), 33% partial response (PR), 21% stable
disease (SD) and 25% progressive disease (PD). The ORR
in patients receiving IL-2 monotherapy was 35%: 15% CR,
20% PR, 25% SD and 40% PD. Seven patients assigned to
IL-2 subsequently received SBRT + IL-2. One CR and two
PRs were observed in the crossover group. There was no
difference in progression-free or overall survival (OS). At 5
years the OS was 26% in the SBRT + IL-2 group and 25%
in the IL-2 monotherapy group. The disease control rate
(DCR) was higher in the SBRT + IL-2 group (75% vs 60%,
p=0.34).
Conclusions SBRT + IL-2 induced more objective
responses with a higher DCR compared to IL-2
monotherapy in MM. IL-2 monotherapy resulted in
a significantly higher ORR than anticipated. Some
patients in the crossover group also achieved objective
responses.
Trial registration number NCT01416831.

Background
The first publication reporting the efficacy
of high-
dose (HD) interleukin-2 (IL-2) for
patients with metastatic melanoma appeared
in 1985; a subsequent manuscript describing
270 patients treated with HD IL-2 reported
a complete response (CR) rate of 6% and
a partial response (PR) rate of 10% with a
median duration of response greater than 40
months.1 2 Over 70% of patients achieving a
CR and approximately 15% of those achieving
a PR were alive and without recurrence at 15
years identifying HD IL-2 as the first curative
immunotherapy regimen for patients with
stage IV melanoma. Since 2010 there have
been many significant advances in melanoma treatment including the development
of checkpoint antibodies, first anti-
CTLA-4
PD-1 with
using ipilimumab,3 then anti-
nivolumab,4 and now the use of combined
T-
cell checkpoint therapy with ipilimumab
and nivolumab showing an objective response
of 58% and complete response of 19% associated with 3-year survival of 52%.5 Clinically
significant responses and disease control
have also been demonstrated with anti-PD-1
checkpoint monotherapy with nivolumab or
pembrolizumab.6 7 Targeted therapy with the
BRAF and MEK inhibitors vemurafenib and
cobimetinib, dabrafenib and trametinib or
cobimetinib and encorafenib are also associated with a high probability of objective
response and improvement of disease-
free
and overall survival. Complete regressions
with BRAF-targeted therapy are also possible
and associated with improved long-
term
outcomes.8 Improved survival has been validated for T-cell checkpoint inhibitor (CPI)
therapy and BRAF-
targeted therapy combinations, yet the proportion of patients with
complete and durable responses who require
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subsequent therapy based on progression-
free survival
probability is at least 60% and may be as high as 80% at
3 years.5 6 Furthermore, the best therapy or therapeutic
sequence for patients who have melanoma progression
after CPI or targeted therapy is not yet known and most
patients with metastatic disease still die as a consequence
of melanoma as illustrated by recent survival statistics.9
Preclinical studies indicate that exposure of tumor cells
to high-dose radiation can augment the release of inflammatory cytokines, upregulate expression of MHC class I,
B7.1, and Fas/CD95.10–15 Tumor cells injured by radiation
can also release damage-
associated molecular patterns
(DAMPs) such as HMGB1 and double-
stranded DNA
(dsDNA) that can trigger a TLR4-
dependent cognate
immune response.16 High-dose per fraction radiation also
increases tumor infiltrating activated CD8+ T cells and has
been associated with enhanced tumor control at distant
sites when combined with immunomodulatory agents in
preclinical studies.17–19
We observed that patients with melanoma or renal cell
carcinoma (RCC) who had radiation for urgent palliation
in the week before IL-2 had a surprisingly high objective response in lesions that were not radiated following
high-
dose IL-2. This observation led us to perform a
pilot phase I trial of stereotacticbody radiation therapy
(SBRT) and IL-2 in which the primary objective was to
determine the maximum tolerated dose (MTD) of SBRT.
We observed an objective response of 71% in previously
untreated patients with metastatic melanoma and 60% in
RCC. There was no increase in the toxicities associated
with high-dose IL-2 and no dose-limiting toxicities associated with radiation. These encouraging initial clinical
signals were the basis for the phase II trial reported here.
The primary clinical aim of the phase II study was to
compare the objective response of SBRT + IL-2 versus IL-2
monotherapy in the non-
irradiated lesions. Secondary
objectives included an evaluation of crossover to SBRT +
IL-2 in patients who progressed on IL-2, and an investigation of DAMPs, which as stated above may be important
immune adjuvants that influence the response to immunotherapy and radiation. Due to the technical complexities of measuring HMGB-1 dsDNA in the peripheral
blood, we chose instead to measure surrogate markers
for DAMPs including uric acid, lactate dehydrogenase
(LDH) and phosphorus, which reflect cell and DNA
damage after radiation and procalcitonin, which reflects
tissue injury and cytokine induction.
This study started in late 2011, which was the time that
T-cell checkpoint antibodies and BRAF-targeted therapy
were entering clinical practice. The availability of these
melanoma treatment options significantly influenced
accrual to this clinical trial and the clinical histories of
the study population as detailed below.

Medical Center (PPMC), Providence Cancer Institute.
The main eligibility criteria were patients >18 years old,
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1, histological confirmation of melanoma, at least one metastatic lesion amenable to SBRT
in the lung, mediastinum or liver, and at least one other
metastatic site not treated with SBRT. Cardiopulmonary
status sufficient to tolerate HD IL-2 was required20 and
patients had essentially normal hematologic, hepatic,
and renal function before treatment. Exclusion criteria
included having no metastatic site amenable to SBRT;
active infection; previous radiation to sites proposed for
SBRT; need for chronic steroids or active autoimmune
disease. Signed informed consent was obtained prior to
enrollment. The study was listed on Cancer.gov. There
were no restrictions for prior melanoma systemic therapies or for brain metastases as long as they were stable or
improved after local therapy (surgery and/or stereotactic
radiation).

Methods
Study design and population
A single institution phase II study was conducted at the
Earle A. Chiles Research Institute, Providence Portland

Procedures
SBRT planning was performed using a four-dimensional
CT scan with the patient in the treatment position immobilized with the BodyFIX (Elekta, Atlanta, Georgia). The
internal target volume was delineated on the planning CT
and a 3 to 5 mm planning target volume margin was used.
An intensity modulated radiation therapy treatment plan
with 6 MV photons was generated using Pinnacle V.9.0
software (Philips Medical Systems, Andover, Massachusetts) based on tumor location and geometry. The target
was localized with cone beam CT before each treatment,
which was delivered on the Synergy S (Elekta, Atlanta,
Georgia) machine. A minimum of one and a maximum of
three lesions were treated with SBRT. Clinical criteria were
used to select the lesion(s) to be treated with radiation.
Lesions that were causing pain or compressing a hollow
viscus (such as bronchus or bile duct) were prioritized
over others. In patients where no symptoms were being
caused by their metastatic sites, then the lesion deemed
safest to administer radiation was selected. A maximum
diameter of 7 cm was allowed for each SBRT target lesion.
All patients were treated by two of the authors (SKS and
MC). The first eight patients were treated with one SBRT
dose on the Friday before the Monday on which IL-2 was
to start. The subsequent 16 patients were treated with two
SBRT doses to the target lesion on the Wednesday and
Friday before the Monday IL-2 start. The protocol was
modified due to the observation that a melanoma patient
treated with one SBRT dose had progression of the radiated lesion.
Patients who signed informed consent were assigned to
treatment group in a 1:1 proportion using randomization
by the closed envelope method. Of the 50 patients who
signed consent, six were excluded (three due to rapid
melanoma progression during screening, two due to
cardiac ischemia on exercise tolerance testing and one
due to insurance issues).
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Interleukin-2 (Prometheus Pharmaceuticals, Dallas,
Texas) treatment began on the Monday following the last
radiation treatment and was administered at 600,000 IU
per kilogram intravenousbolus infusion every 8 hours ×
14 planned doses with an additional cycle given after a
16-day hiatus (two cycles=one course of IL-2). Imaging
was obtained after each course and patients with tumor
regression could receive up to three courses. After IL-2
was completed, imaging was obtained every 3 months
until progression or 24 months of follow-up. If patients
did not have progression at 24 months, then imaging was
obtained every 4 months through 3 years after the start
of IL-2 and then every 6 months in year 4 and thereafter.
Patients assigned to the IL-2 monotherapy group and
who showed progression of melanoma after course 1
could receive SBRT and additional IL-2 cycles contingent
on response. We employed PPMC Biotherapy Program
guidelines for IL-2 management, which are a modification of published IL-2 dosing rules.20 21
This protocol used a modified version of the Response
Evaluation Criteria in Solid Tumors (RECIST) V.1.1.22
The overall response assessment included all measurable
and non-
measurable target lesions except the lesions
treated by SBRT, which were assessed separately. Both
CT and positron emission tomography imaging were
employed to assess response. A further modification of
RECIST criteria was used to assess tumor bulk as reported
in online supplementary figure 3 (absolute spider plots).
The sum of the long axis diameter of the largest 30 tumor
deposits was added and compared over time.
Markers of tumor lysis, inflammation and immune
activation were explored by measuring serum lactate
dehydrogenase, procalcitonin, uric acid and phosphate
as surrogate markers of cytotoxicity-
mediated antigen
release with measurements obtained at baseline, after
radiation but before IL-2 and after IL-2 was completed
in cycle 1.
Outcomes
The primary study endpoint was to determine the best
overall tumor response rate of high dose IL-2 versus
SBRT + high-dose IL-2 using RECIST criteria applied
to all target and non-target lesions with the exclusion
of sites treated with SBRT. We assumed in designing the
study that the objective response to IL-2 monotherapy
would be 16% based on other published data23 while
the response to SBRT + IL-2 would be 60% based on
our initial pilot study.24 Using the Pearson χ2 test with
continuity correction, enrolling 22 patients per group
(44 total) would have an 80% power to detect a difference using the response assumptions detailed above. For
patients who received SBRT after progression on IL-2
monotherapy, the response rate was recorded, but not
counted in the assessment of overall tumor response for
the primary objective. The secondary objectives were
hypothesis generating and were not included in determining the sample size.
Curti B, et al. J Immunother Cancer 2020;8:e000773. doi:10.1136/jitc-2020-000773

Statistical analysis
Baseline characteristics were compared using Fisher’s
exact tests and Wilcoxon rank-sum test for continuous
and categorical variables, respectively. The endpoint for
overall survival (OS) was the time from the date treatment started to death. The endpoint for progression-
free survival (PFS) was the time between the start of IL-2
treatment to the event related to the disease (progressive
disease (PD) after initial CR, PR or stable disease (SD))
or death. To examine whether there was a difference in
OS and PFS between two treatment groups, Kaplan-Meier
and Cox proportional-hazards regression analyses were
performed. The association of age, gender, LDH, BRAF
status with OS and PFS were also evaluated. In addition,
logistic regression analyses were employed to determine
the independent predictors of disease control rate (DCR)
(CR/PR/SD). All statistical analyses were performed
using R V.3.5.0 (R Core Team, 2018).
Results
Population
Forty-
four eligible patients with advanced melanoma
enrolled and were treated from August 2011 through
March 2017. Twenty-four patients were randomized to
receive SBRT + IL-2 and 20 patients were assigned to
IL-2 monotherapy. Of the eight patients randomized to
IL-2 whose melanoma progressed after the first imaging,
seven agreed to participate in the crossover portion of
the study. Five additional patients signed consent but
withdrew consent before receiving treatment as they
opted for other systemic therapies and were not included
in this analysis. Table 1 summarizes clinical characteristics and treatments before and after IL-2. There were
no statistically significant differences in demographic
characteristics, or baseline tumor burden, although
patients assigned to the SBRT + IL-2 group tended to
have a greater tumor burden compared with the IL-2
monotherapy group (online supplementary table 1). The
mean LDH among patients assigned to SBRT + IL-2 was
389 compared with 263 IU/L in patients assigned to IL-2
monotherapy (upper limit of normal 268 IU/L). A higher
proportion of patients in the IL-2 monotherapy cohort
had melanomas with a BRAF V600E mutation compared
with those assigned to SBRT + IL-2 (55% vs 29%, p=0.1).
Outcomes
Figure 1 shows waterfall plots of best overall response
using RECIST 1.1 criteria after SBRT + IL-2 of the target
lesions not treated with SBRT (1A) and IL-2 monotherapy
(1B). The objective response in the SBRT + IL-2 group
was 21% CR, 33% PR, 21% SD and 25% PD. Among the
patients who received SBRT + IL-2, the best response
was determined after course 1 in eight patients (33%),
after course 2 in eight patients (33%) and after course
3 in eight patients (33%). Patients receiving IL-2 monotherapy had 15% CR, 20% PR, 25% SD and 40% PD. The
DCR was 75% in the SBRT+IL-2 group and 60% in the IL-2
3
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Table 1 Clinical characteristics and treatments of study
participants by group
SBRT + IL-2 IL-2
Male
Female

18
6

16
4

Age (mean)

53

57.5

BRAF status
 Mutated/wild type/unknown
Baseline LDH (mean) (upper
limit of normal 268 IU/L)

7/14/3
389

11/5/4
263

Prior therapy
 Surgery (%)

24 (100)

20 (100)

 Radiation (n)

1 (4)

3 (15)

 BRAF therapy (n)

1

0

 Immune checkpoint (n)

5

3

4

5

11

6

Subsequent therapy
 BRAF therapy (n)
 Immune checkpoint (n)

Metastatic sites at start of treatment
 Lung (%)

64

74

 Liver (%)

36

37

 Lymph node (%)

36

53

 Bone (%)

14

5

 Subcutaneous (%)

27

11

 Brain (%)

5

5

 Soft tissue (%)

50

21

 Adrenal (%)

14

0

Figure 1 (A) Waterfall plot of best response to SBRT + IL-2.
The radiated lesions were excluded from RECIST assessment
of target lesions. The responses of patients who participated
in the crossover portion of the study are excluded from
this analysis. (B) Waterfall plot of best response, IL-2
monotherapy before crossover. The responses to additional
IL-2 cycles after crossover are excluded. IL-2,interleukin-2;
RECIST, Response Evaluation Criteria inSolid Tumors; SBRT,
stereotactic body radiation therapy.

Sum of diameters of target lesions using modified RECIST
 cm (median)

8.2

6.5

 cm (mean)

5.1

5.3

monotherapy group (p=0.34). Among the patients who
received IL-2 monotherapy, the best response was determined after course 1 in 11 patients (55%), after course 2
in two patients (10%) and after course 3 in seven patients
(35%). Seven patients assigned to IL-2 monotherapy
participated in the crossover. One patient achieved a CR
and two achieved PR of the lesions not treated with SBRT.
Progression-
free survival is depicted in figure 2A and
overall survival in figure 2B. There was no difference in
progression-free or overall survival among the treatment
groups. The 1-year, 3-year and 5-year survivals were 71%,
41% and 26%, respectively, in the SBRT + IL-2 group.
For the IL-2 monotherapy group (including crossover
patients), the 1-year, 3-year and 5-year survivals were 65%,
35% and 25%, respectively. The 1-year, 3-year and 5-year

survivals for IL-2 monotherapy excluding the crossover
group were 62%, 46% and 29%, respectively.
The clinical outcomes and subsequent treatments of
all 44 patients over time are summarized using swimmers
plots (figure 3A for the SBRT + IL-2 group and figure 3B
for IL-2 monotherapy + crossover groups). Of the 24
patients assigned to the SBRT + IL-2 cohort, four received
BRAF-targeted therapy and 14 received CPI at the time of
progression. This includes the 13 patients who achieved
an initial CR or PR by RECIST criteria to SBRT + IL-2.
Of the seven patients who achieved an initial CR or PR
after IL-2 monotherapy, four required subsequent treatments. Five patients received CPI therapy before SBRT
+ IL-2 and three before IL-2 monotherapy. Five of the
eight patients receiving CPI before enrolling on this trial
had responses to IL-2, two of which were durable (lasting
more than 1 year). Seven of the 18 patients who received
CPI after SBRT + IL-2 had a partial regression of disease
including one crossover patient. The 11 patients who did
not achieve a PR with subsequent CPI had a brief interval
of stability followed by progression of their melanoma.
One of three patients who received IL-2 monotherapy
(and no radiation) achieved a PR with subsequent CPI.
Of the seven patients participated in the crossover, five
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Sum of diameters of 30 largest lesions
 cm (median)
 cm (mean)

19.7
11.4

13.7
10.7

LDH, lactate dehydrogenase; RECIST, Response Evaluation
Criteria in Solid Tumors.
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Figure 2 (A) Kaplan-Meier plot of progression-free survival by treatment group. Patients who participated in the crossover
group are included with the IL-2 group. (B) Kaplan-Meier plot of overall survival by treatment group. Patients who participated in
the crossover group are included in the IL-2 group. IL-2,interleukin-2; OS, overall survival; PFS, progression-freesurvival; SBRT,
stereotactic body radiationtherapy.

in relation to the absolute tumor burden (sum of long-
axis diameters of all lesions on CT).

received BRAF-targeted therapy and five received CPI at
the time of melanoma progression. Two patients in the
SBRT + IL-2 group and three patients assigned to the
IL-2 monotherapy group have not required additional
systemic or local treatments for their melanoma.
As described by others, patients with higher than normal
baseline LDH levels had a lower probability of response
(p=0.08). We also performed an analysis of the response
of individual tumor lesions based on the clinical observation that many patients experienced mixed responses
with regression of some lesions and progression or the
development of new lesions. This analysis did not change
the response interpretation as defined by RECIST. Online
supplemental figures S1−S3 illustrate the tumor response

Response of lesions treated with SBRT
Patients received SBRT either as part of their initial cohort
assignment before cycle 1 IL-2 or if they progressed
after IL-2 monotherapy and opted to participate in the
crossover group. Crossover patients received SBRT
before cycle 3 of HD IL-2. When the protocol started
enrolling patients, only one SBRT dose was specified as
there appeared to be no difference in the outcome of
patients in the completed pilot study comparing one,
two or three SBRT doses before IL-2.24 However, among
the patients assigned to a single SBRT dose we observed
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Figure 3 (A) Swimmers plot for SBRT + IL-2 patients. Each bar represents an individual patient’s treatment history with the bar
color indicating survival status and subsequent treatment. (B) Swimmers plot for IL-2 patients (including crossover). Each bar
represents an individual patient’s treatment history with the bar color indicating participation in the crossover, survival status
and subsequent treatment. IL-2,interleukin-2; SBRT, stereotactic body radiation therapy.

rapid progression of a liver lesion. The protocol was
modified to administer two SBRT doses thereafter. Eight
patients assigned to the SBRT + IL-2 group received one
SBRT dose and 16 patients received two SBRT doses.
Six of the seven patients in the crossover group received
two SBRT doses. Table 2 summarizes the characteristics
of the lesions treated with SBRT. The median diameter
of lesions in patients assigned to the SBRT cohort was
smaller compared with the patients who participated
in the crossover (2.5 vs 4.5 cm, p=0.08). There was no
significant difference in the organ site selection for SBRT
comparing the groups. Among patients who experienced
regression of tumors at the non-
irradiated sites, the

median size of the lesions treated with SBRT was 1.6 cm
compared with 2.9 cm in patients whose lesions in non-
irradiated sites did not regress. Of the 31 tumors treated
in the SBRT cohort, 27 decreased in size (15 complete
and 12 partial responses using RECIST criteria) and 4
increased in size. In the crossover group, nine lesions
were treated of which seven decreased (three complete
and four partial responses of the irradiated lesions) and
two increased. We also investigated the degree and duration of responses in non-irradiated lesions in relation to
the site chosen for SBRT (summarized in table 3). The
study was not powered to detect differences in response
based on the site selected for SBRT; however, we observed
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Table 2 Characteristics of the lesions treated with SBRT.
SBRT

SBRT crossover

Median lesion size (cm)
Baseline (range)

2.5 (0.5 to 6.4)

4.3 (1.6 to 7.1)

Assessment 1

1.3 (0 to 5.5)

2.5 (0 to 7.5)

Assessment 2

0 (0 to 6.1)

2.5 (0 to 6.3)

Median lesion # treated per
patient

1

1.5

Sites treated
Lung (%)

14 (45)

2

Liver (%)

11 (35)

4

LN (%)

4 (13)

3

Other (%)

2 (6)

0

Lesions that progressed (%)*

5 (16)

2 (22)

Lesions that regressed (%)

25 (81)

7 (78)

Lesions with no change (%)

1 (3)

0 (0)

15 (48)

3 (33)

Lesions BORR=0 (%)

#, number; BORR, best overall response rate; LN, lymph node; SBRT,
stereotactic body radiation therapy.

no difference in response based on 1 versus >1 site radiated or the number of radiation fractions (50% vs 56%).
There was a trend favoring response of irradiating lung
tumors versus liver lesions or other sites (58% vs 33%).
Treatment received and safety
The median number of IL-2 doses for the first and second
cycles of therapy were 10 and 7 in the SBRT + IL-2 group
and 9 and 8 in the IL-2 monotherapy group (p=NS). This
was comparable to the median number of IL-2 doses
tolerated historically by other patients in our Biotherapy
Program who did not receive SBRT.21
Anticipated toxicities from IL-2 were observed and
included hypotension requiring vasopressor support,

pulmonary capillary leak with hypoxemia, fever, rigors,
myalgias, arthralgias, pruritus, erythematous rash, diarrhea, nausea, electrolyte abnormalities, elevations of
hepatocellular enzymes, azotemia, peripheral neuropathy, mental status changes and immune-mediated hypothyroidism. These toxicities were transient (with the
exception of immune-
mediated hypothyroidism) and
resolved using supportive medications and holding IL-2
doses. There were no long-lasting toxicities from IL-2 with
the exception of hypothyroidism requiring levothyroxine
in 16 patients and vitiligo in 6 patients, all of whom had
regression of melanoma during treatment.
One patient assigned to the SBRT + IL-2 cohort developed respiratory failure after cycle 2 IL-2 characterized
by patchy infiltrates in both lungs and outside the radiation ports in the right lateral and left anterior lung
fields. He did not improve on broad-spectrum antibiotics
or after diuresis, bronchodilators, empiric steroids and
mechanical ventilation. Multiple cultures did not reveal
an infectious etiology. Imaging revealed regression of
some of the melanoma deposits in the lungs including
the lesions treated with SBRT as well as other pulmonary metastatic sites. The clinical differential diagnoses
included atypical pneumonia, lymphangitic spread of
melanoma or immune-mediated lung injury. In light of
the patients advanced melanoma, the patient opted for
best supportive care and he died as a consequence of
respiratory failure. The patient did not consent to invasive procedures for biopsy and his family declined to have
an autopsy performed.
Peripheral blood DAMPs
Surrogate markers for DAMPs including uric acid, LDH,
procalcitonin and phosphorus were measured serially
and compared by treatment assignment. Figure 4 shows
baseline and peak values for uric acid and procalcitonin.
Responding patients who received SBRT displayed a

Table 3 Response of non-irradiated lesions in relation to SBRT treated site
SBRT site (n)

% change of non-irradiated
lesions

Median %
change

Mean %
change

Duration (days)

Median duration
days

Liver (7)

–77, 13, –100, 4, 119, −100, 18

4

−18

289, 188, 350, 162, 57, 306, 69

188

Lung (10)

−62, 0, –100, 14, 89, 38, –23,
–100, 41, 0

0

−11

767, 105, 399, 81, 342, 83, 39,
1238, 67, 169

169

Lymph node (4)

–57, –100, –100, –47

−78.5

−76

76, 1726, 690, 258

474

Bone (1)

−53

−53

−53

334

334

Liver + lung (1)

−100

−100

−100

793

793

Lung + bone (1)

−67

−67

−67

129

129

Duration (days)

Median duration
days

SBRT, stereotactic body radiation therapy.

% change

Median %
change

Mean %
change

Liver (2)

–100, –100

−100

−100

157, 278

217

Lung (2)

–100, –18

−59

−41

377, 168

272

Crossover patients

Lymph node (1)

56

56

56

56

56

Liver + lung (1)

−12

−12

−12

83

83
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Figure 4 (A) Uric acid (mg/dL) by treatment group comparing baseline and peak values during cycle 1. In most patients, the
peak uric acid value occurred on day 5 or 6 after IL-2 started. There was no statistically significant difference in the timing or the
peak uric acid level comparing SBRT + IL-2 or IL-2 monotherapy although there was a trend toward high uric acid levels among
SBRT + IL-2 responders compared with non-responders. (B) Baseline and peak procalcitonin (ng/ml) by treatment group during
cycle 1. The peak procalcitonin was observed on day 5 or 6 after IL-2 started. There was no statistically significant difference in
the timing or the peak procalcitonin level comparing SBRT + IL-2 or IL-2 monotherapy although there was a trend toward lower
procalcitonin levels among SBRT + IL-2 responders compared with non-responders. IL-2, interleukin-2; SBRT, stereotacticbody
radiation therapy.

Discussion
The combination of SBRT and IL-2 showed a trend toward
higher response and higher DCR compared with IL-2
monotherapy in patients with advanced melanoma yet
no statistically significant differences in PFS or OS were
observed. We were surprised to observe the much higher
than anticipated objective response of the IL-2 monotherapy arm. As expected, some patients in both arms
achieved durable regressions of their melanoma and did
not require further systemic or local therapy; however,
the majority of patients required subsequent medical,
surgical or radiation therapy to manage their melanoma.
Overall, the duration of response in each group was less

than anticipated based on prior reports with IL-2 monotherapy from our group and others.21 25 The shorter than
anticipated response duration may have been due to prior
therapy altering the immune response or the responsiveness of the melanoma to an IL-2-based regimen. Although
overall survival could not be compared due to the crossover design, the 1-year, 3-year and 5-year survivals for
patients in both arms were clinically relevant. The overall
survival at 1, 3 and 5 years after CPI or BRAF-targeted
therapy independent of IL-2 immunotherapy in patients
with advanced melanoma is significant, yet the reality for
the majority of patients is that multiple lines of systemic
therapy are needed. Our long-term results are similar to
more contemporary reports of patients receiving high-
dose IL-2. For instance, Davar et al, describe 1-year, 2-year
and 3-year survivals of 41%, 20% and 14%, respectively,
in a large single-institution study comprising 243 patients
with advanced melanoma.26 After progression on IL-2, 36
patients were treated with T-cell checkpoint antibodies and
7 (19%) have ongoing response to immunotherapy. The
long-term survival of patients in both treatment groups in
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trend toward higher median uric acid and lower median
procalcitonin levels on days 5 and 6 after the start of IL-2
compared with patients who did not have a response
to SBRT + IL-2 or those assigned to IL-2 monotherapy.
There were no statistically significant changes in any of
the DAMP surrogate markers measured due to patient-to-
patient variation.

Open access
this study was probably influenced by subsequent therapy
in light of the current knowledge about survival benefit of
CPI and BRAF-targeted therapies. Similarly, anti-PD-1 and
anti-CTLA-4 before IL-2 likely influenced IL-2 responses.
Although no prospective study on clinical outcome exists
for the activity of checkpoint inhibitors after IL-2, retrospective observations suggest a higher than anticipated
response to anti-PD-1 following IL-2.25 In this report, 18%
of patients achieved partial regressions of melanoma after
their high-dose IL-2 regimen.
The rationale for investigating the combination of high-
dose per fraction radiation and IL-2 was not based on the
assumption of an abscopal effect. Rather, we hypothesized
that cell death from radiation supplied a source of antigen
for adaptive immune response and that the IL-2 provided
a strong cytokine signal to amplify immune response.27
As a consequence of the radiation-induced cell death,
we also expected to observe higher uric acid levels in
patients who received radiation. In addition, we hypothesized that procalcitonin would be lower as the immune
response would be directed to the radiated tumor and
not manifest systemically as is the case with high-dose
IL-2. There were no statistically significant differences
among the treatment groups due to significant patient-to-
patient variation, but there was a trend toward higher uric
acid and lower procalcitonin in responding SBRT + IL-2
patients compared with non-responders for IL-2 monotherapy. The study was not designed to detect a difference
in clinical outcome based on the site chosen for SBRT,
but none of the patients who had liver as the only site
treated with SBRT achieved control of melanoma. The
mechanism for this lack of response may be related to
fewer CD8 + T cells present in liver metastases and also
decreased CD8 + T cell in tumor-infiltrating lymphocytes
in non-liver sites in melanoma patients having liver metastases.28 The patients who had a pulmonary site chosen for
SBRT had the highest proportion of response. Individual
patients who had both a lung and liver site also achieved
responses. This observation may be a consequence of the
known poorer prognosis of patients who have melanoma
liver metastases compared with melanoma lung metastases. It also suggests that the immune response after
radiation in pulmonary sites may be different compared
with radiation of hepatic sites. We are developing a clinical trial to investigate this hypothesis.
We acknowledge the small sample size, the influence
of the crossover in interpreting response and survival
and the lengthy time to meet accrual goals; however, the
medical management of advanced melanoma changed
dramatically from the time the study opened in late
2011 to the present with at least nine new medicines
or regimens approved by the Food and Drug Administration. These changes in melanoma treatment altered
the referral patterns to our cancer center of untreated
patients compared with our original pilot study, which
treated patients in the first line with SBRT + IL2.24

Conclusions
We observed a modest trend toward higher response
rates with SBRT + IL-2 and higher disease control rate in
patients receiving dual therapy compared with IL-2 monotherapy. A larger study without a crossover group would
be required to address overall survival in the current
era of melanoma treatment in which multiple lines of
therapy are commonly administered to patients with
advanced melanoma. This study also illustrates that SBRT
+ IL-2 has activity in patients after progression on IL-2
monotherapy, CPI or BRAF-targeted therapy, the latter
of which are the current standards of care for patients
with advanced melanoma. Individuals with symptomatic
metastatic sites amenable to treatment with high-dose per
fraction radiation and physiological reserve sufficient to
tolerate HD IL-2 should be considered for SBRT + IL-2 in
the second or third line.
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